Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally

Superstring Capital Management established a new $5.82 million position in Vir Biotechnology by acquiring 730,548 shares in Q1 2026. The investment appears to be a bet on upcoming clinical catalysts rather than current financials, with Vir expecting Phase 3 hepatitis delta data in Q4 2026 and pivotal Phase 3 oncology trials in 2027. Despite being unprofitable, the company has a strong balance sheet with $809.3 million in cash and runway into late 2028.

05/23/2026, 6:13 PM • The Motley Fool

"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

A new generation of immuno-oncology therapies targeting historically immunotherapy-resistant solid tumors like prostate and pancreatic cancer is advancing rapidly through clinical trials in 2026. Four distinct mechanistic approaches—including NK cell engagers, oncolytic virus immune-primers, and tumor microenvironment-conditional antibodies—are being developed by multiple biotech companies, with over $1.7 billion in dealmaking activity. GT Biopharma's GTB-5550 NK cell engager and Vir Biotechnology's VIR-5500 PSMA-targeted T-cell engager represent leading programs in this emerging therapeutic landscape.

05/14/2026, 10:55 AM • GlobeNewswire

Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000

Vir Biotechnology CEO Marianne De Backer sold 72,559 shares worth $664,350 on April 6, 2026, representing 6.76% of her holdings. The sale aligns with her historical selling patterns and appears to be income supplementation rather than a loss of confidence. The company has shown positive momentum with encouraging clinical trial results for VIR-5500 and a significant partnership deal with Astellas Pharma worth $315 million.

04/12/2026, 9:13 AM • The Motley Fool

Stock Market Today: S&P 500 Futures Slip As Dow, Nasdaq 100 Gain Following Trump's Tariff Threat — Whirlpool, Uber, HP In Focus (UPDATED)

U.S. stock futures rose on Tuesday following Monday's sell-off triggered by AI-related economic concerns and a viral 'Global Intelligence Crisis' report. Market sentiment remains cautious amid Trump's tariff threats and geopolitical tensions. Key movers include Keysight Technologies surging 16% on strong earnings, Vir Biotechnology jumping 63% on revenue beat, and Whirlpool plunging 7.46% after announcing an $800 million capital raise.

02/24/2026, 8:31 AM • Benzinga

Stock Market Today: Dow Jones, Nasdaq 100 Futures Gain Amid AI-Led Sell-Off, Trump's Threat To Trading Partners—Whirlpool, Uber, HP In Focus

U.S. stock futures rose on Tuesday following Monday's sell-off triggered by AI-related economic concerns and deflationary depression fears. Major indices showed modest gains in premarket trading. Key movers included Keysight Technologies surging 16% on strong earnings, Vir Biotechnology jumping 63% on revenue beat, and Whirlpool plunging 7.5% after announcing an $800 million stock offering. Market sentiment remains cautious amid Trump's tariff threats and geopolitical tensions.

02/24/2026, 5:16 AM • Benzinga

Is Alnylam Pharmaceuticals a Millionaire Maker?

Alnylam Pharmaceuticals, a biotech company focused on RNA interference (RNAi) therapies, has shown significant growth since its 2004 IPO. The company has multiple approved drugs for rare diseases and a promising pipeline of potential treatments across various medical conditions.

12/07/2025, 2:25 AM • The Motley Fool

Vir (VIR) Q2 Revenue Drops 61%

Vir Biotechnology reported a Q2 2025 net loss of $0.80 per share, with revenues of $1.2 million. The company advanced its clinical pipeline in hepatitis delta and oncology, maintaining $892.1 million in cash reserves while continuing to invest in research and development.

08/07/2025, 12:32 AM • The Motley Fool